While P-gp expression was only found in 60/261 (22.9%) of de novo AML patients, it was found in 23/24 (95.8%) of patients with the drug-refractory disease and 24/30 (80.0%) of those with relapsing AML[60]. Here, PGP is linked to acute myeloid leukemia.